Lab VerifiedGLP-1 / GIP / glucagon triple agonist
Retatrutide
200mg · sterile vial
An investigational triple-receptor agonist studied in metabolic research. Availability and candidacy are strictly provider-determined.
What this involves
Complete a short assessment. A licensed provider reviews your information and determines whether this product is appropriate — nothing is dispensed without that review.
Research Context
Retatrutide targets GLP-1, GIP, and glucagon receptors and remains under clinical investigation. Provider review is required; nothing here is a guarantee of prescription.
Detailed monographs, dosing references, and per-batch Certificates of Analysis are provided through your provider and our verification library.
Why USA Direct Rx
- Licensed US prescriber review
- US pharmacy dispensed
- Lab-verified purity per batch
- Real card payments — no crypto or cash-app
- Discreet, tracked shipping
Commonly Paired
Tirzepatide
View
Compliance & Legal Status
Products are dispensed only pursuant to a valid prescription issued by a licensed provider after review of your assessment. Submitting an assessment is not a guarantee of prescription. Nothing on this page is medical advice or a claim to diagnose, treat, cure, or prevent any disease.
